Document is current

Article History

First Online: 25 January 2020

Compliance with Ethical Standards

:

: The study was funded by Novartis Pharma AG, Basel.

: MØ has received research support and/or consultancy/speaker fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Contocor, Eli-Lilly, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo Nordisk, Orion, Pfizer, Regeneron, Roche, Schering-Plough, Takeda, UCB and Wyeth. UK has received grant and research support and consultancy fees from AbbVie, Biocad, Biogen, Chugai, Eli Lilly, Grünenthal, Janssen, MSD, Novartis, Pfizer, Roche and UCB. DP reports grants and personal fees from AbbVie, personal fees from BMS, personal fees from Lilly, grants and personal fees from MSD, grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Roche, personal fees from UCB, personal fees from Celgene, grants or consulting fees from Janssen, outside the submitted work. LG has received grant/research support from UCB, AbbVie, Amgen, Novartis, Pfizer; and consulting fees from Galapagos, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. XB and EYL has no conflicts of interest to disclose. BP, RM, AR and HS are employees and shareholders of Novartis.

: This study was designed and will be implemented, executed reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations, and with the ethical principles laid down in the Declaration of Helsinki. The study was approved by the institutional review boards or independent ethics committees at each participating center.